Denali Therapeutics Inc

DNLI remains in a Stage 2 uptrend supported by a recently confirmed Bullish Pivot Point with rising EMAs, but the short-term rejection at the 9- and 20-day EMAs warrants patience, favoring deferred entries around the rising 50-day SMA or upon clear EMA acceptance for a higher-probability momentum continuation.

• ↑Q2 AVLAYAH revenue $3.6M; Q3 guidance $10–12M
• ↑Payer coverage secured for >50% of covered lives across 14 states
• ↓Q2 net loss $127.6M highlights ongoing unprofitability